Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline

Monday, November 19, 2007 General News J E 4
WALTHAM, Mass., Nov. 19 Decision Resources, one of theworld's leading research and advisory firms for pharmaceutical and healthcareissues, finds that the most promising antibiotics in development for thetreatment of community-acquired pneumonia are intravenous agents that will beused in the hospital setting, including Johnson & Johnson/Basilea'sceftobiprole and Forest's ceftaroline. The broad spectrum of these next-generation cephalosporins includes activity against methicillin-resistantStaphylococcus aureus.

The new Pharmacor report entitled Community-Acquired Pneumonia finds thatin 2006 antibiotics generated more than $800 million while the pneumococcalvaccines garnered approximately $1.5 billion in sales in the majorpharmaceutical markets. Decision Resources forecasts that the hospital segmentof the community-acquired pneumonia market will experience considerablegrowth, driven by rising resistance rates that will encourage the uptake ofnovel products. However, growth in the outpatient market will be limited overthe next decade given its maturity, increased availability of generic agentsand the upcoming patent expiry of products such as Johnson & Johnson'sLevaquin. The launch of vaccines in late-stage development fromGlaxoSmithKline and Wyeth expand upon the serotype coverage of Wyeth'sblockbuster vaccine, Prevnar, and will drive growth in the pneumococcalvaccine market.

"Community-acquired pneumonia is an important indication for antibioticdrug developers because it represents a sizeable inpatient population and canbe a gateway indication to the large outpatient respiratory tract infectionsmarket," said Kaitlyn Sullivan, analyst at Decision Resources. "Drugresistance will lead to a shift in prescribing practices in the coming years.Physicians interviewed expressed increasing concern about rising levels ofmacrolide resistance in the outpatient setting."

About The Report

Community-acquired pneumonia examines the opportunities remaining for newantibiotics, therapeutics, and vaccines in a relatively mature and competitivemarket, and it describes ways that companies can capitalize on theseopportunities. The report examines current therapies, unmet needs, and trendsin medical practice that are essential to understanding the community-acquireddrug market. It also provides comprehensive coverage of therapeutic agents andvaccines in late-stage development for community-acquired pneumonia anddetails a forecast covering market segments such as inpatient, outpatient,pediatric vaccine, and adult vaccine segments in seven major pharmaceuticalmarkets (United States, France, Germany, Italy, Spain, United Kingdom, andJapan).

About Decision Resources

Decision Resources ( is a world leader inmarket research publications, advisory services, and consulting designed tohelp clients shape strategy, allocate resources, and master their chosenmarkets.

All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563

SOURCE Decision Resources, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Raydiance Collaborates With Rutgers University and...
Biomoda Hires Senior Scientist to Head Research & ...